Welcome to our dedicated page for Veradermics news (Ticker: MANE), a resource for investors and traders seeking the latest updates and insights on Veradermics stock.
Veradermics (MANE) news is driven mainly by clinical development updates for VDPHL01, the company’s investigational oral, non-hormonal, extended-release minoxidil tablet for pattern hair loss. Because Veradermics is a late-stage biopharmaceutical company, its most important updates often involve clinical trial results, study design, enrollment progress, safety observations, and data presentations in dermatology settings.
News about the company frequently focuses on male and female pattern hair loss studies, including Phase 2, Phase 2/3, and Phase 3 work. Updates may cover topline data, subgroup analyses, poster presentations, oral presentations, conference calls, and comparisons with existing minoxidil formulations when the company discloses those analyses. These items matter because VDPHL01 is the company’s lead program and defines much of the investment case for MANE stock.
Veradermics also generates financial and corporate news. Its releases and filings have covered quarterly financial results, clinical progress summaries, investor conference participation, public offerings, private placements, pre-funded warrants, and IPO registration materials. For a clinical-stage issuer, financing and cash-related disclosures are closely tied to the company’s ability to continue trial activity and prepare for potential regulatory and commercial steps.
Regular review of Veradermics news can help readers track how the company’s dermatology pipeline develops, how VDPHL01 data are reported, and how corporate filings align with public clinical updates.
Veradermics (NYSE: MANE) launched a proposed public offering of 3,350,000 securities consisting of common stock and, for certain investors, pre-funded warrants, with an underwriter option for an additional 502,500 shares.
The company expects a concurrent private placement of pre-funded warrants to entities affiliated with Suvretta Capital; total securities to be issued across both transactions remain 3,350,000. The registration statement is filed but not yet effective and the offering is subject to market conditions.
Veradermics (NYSE: MANE) reported topline Phase 2/3 Part A results for oral VDPHL01 in male pattern hair loss, from a 519-patient randomized trial. VDPHL01 met all primary and key secondary endpoints, showing mean non-vellus TAHC increases of 30.3 (QD) and 33.0 hairs/cm² (BID) versus 7.3 hairs/cm² placebo at Month 6.
Patient-reported improvements were 79.3% (QD) and 86.0% (BID) versus 35.6% placebo; statistically significant separation occurred as early as Month 2. Safety profile showed no treatment-related SAEs or cardiac AESIs.
Veradermics (NYSE: MANE) will host an investor conference call and live webcast on Monday, April 27, 2026 at 8:00 a.m. ET to review topline results from Part A of its randomized, double-blind, placebo-controlled Phase 2/3 '302' trial of VDPHL01 in males with mild-to-moderate pattern hair loss.
The event and slides will be available on the company's Investors Events page, and a replay will be posted after the call.
Veradermics (NYSE: MANE) reported Q4 and full-year 2025 results and clinical progress. The company closed an upsized IPO raising approximately $294.8M in February 2026; cash was $141.9M as of Dec 31, 2025, and combined proceeds are expected to fund operations into 2029.
Enrollment completed in male registrational trials Study 302 and Study 304 (>1,000 male participants); topline readouts expected in 1H 2026 (Study 302) and 2H 2026 (Study 304). Study 306 in females is enrolling (>500 planned). R&D, G&A, and net losses widened in 2025 versus 2024.
Veradermics (NYSE: MANE) will present three abstracts at the 2026 American Academy of Dermatology Annual Meeting in Denver, Mar 27–31, 2026, reporting blinded investigator comparisons of an extended‑release oral minoxidil (VDPHL01) versus topical and immediate‑release formulations and social listening analyses of patient experiences with pattern hair loss.
The presentations include an e-poster on VDPHL01 efficacy and two posters summarizing social listening research across hundreds of thousands of online conversations, with scheduled times on Mar 27 at the Colorado Convention Center.
Veradermics (NYSE: MANE) announced management will attend two investor conferences in Miami in March.
CEO Reid Waldman, M.D. will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 10, 2026 at 4:20 p.m. ET. A live webcast and a ~30-day replay will be available on the company’s investor Events page.
Forgent Power Solutions (NYSE: FPS) marked its early February IPO by ringing the NYSE Opening Bell on February 12, 2026, after shares rose 22% since trading began. The NYSE pre-market update noted broader market moves after a 130,000 jobs print from the Bureau of Labor Statistics.
The NYSE also highlighted Veradermics (NYSE: MANE) and announced a new NYSE Texas Advisory Board to support listings and trading in the Southwestern U.S.
Veradermics (NYSE: MANE) completed enrollment across both Phase 3 male trials of oral VDPHL01, totaling approximately 1,000+ male participants. Topline data from the initial '302' trial is expected in H1 2026, with the '304' confirmatory male study topline in H2 2026. The company is also recruiting for a female Phase 2/3 trial.
VDPHL01 is an extended-release oral minoxidil formulation designed to minimize plasma concentration spikes associated with cardiac activity while delivering sustained hair‑follicle exposure.
Veradermics (NYSE: MANE) closed its upsized initial public offering of 17,339,294 common shares at $17.00 per share, including the full exercise of the underwriters' 2,261,647-share option. Gross proceeds were approximately $294.8 million before underwriting discounts, commissions, and expenses.
All shares were sold by Veradermics and began trading on the New York Stock Exchange on February 4, 2026. Jefferies, Leerink Partners, Citigroup, and Cantor acted as joint book-running managers. Registration statements were filed with and declared effective by the SEC.
Veradermics (NYSE: MANE) priced an upsized initial public offering of 15,077,647 shares at $17.00 per share, raising approximately $256.3 million in gross proceeds before fees. The company expects NYSE trading to begin on February 4, 2026 and closing on February 5, 2026, subject to customary conditions.
The underwriters received a 30-day option to purchase up to an additional 2,261,647 shares. Jefferies, Leerink Partners, Citigroup, and Cantor are joint book-running managers.